NR 566 Advanced pharmacology care of the family midterm reviw 2021 – 2022

NR 566 / NR566 Advanced Pharmacology Care of the Family Midterm Review| LATEST 2021

/2022 | Chamberlain College

1. How to measure the therapeutic effect of HIV therapy
   • –  RNA LEVELS o baselineo2-4 weeks, no later than 8 weeks every 4-8 weeks until suppressed after suppressed every 3-4 months
   • –  Long-term virologic suppression x2 years every 6 months
   • –  any change in status = chemo/steroids every 3 months
2. Protease Inhibitor (PIs) Lopinavir – high-risk patients

– ORAL solution: Contraindicated for full-term infants (until 14 days after birth) and premature (until 14 days after due date)

cardiac disease or prolonged QT

3. Protease Inhibitor (PIs) Lopinavir – Lifespan considerations

– Children: Safe after 14 days old

– Pregnancy: approved w/ higher risks

4. Protease Inhibitor (PIs) Lopinavir/ritonavir – adverse effects

– – QT prolongation

5. Protease Inhibitor (PIs) Saquinavir – Lifespan considerations
   • –  Children
     Not identified as safe/efficient in children younger than 16
   • –  Pregnancy
     safest PI for pregnancy
   • –  HIV treatment is recommended in pregnancy
6. Protease Inhibitor (PIs) Saquinavir – adverse reactions

– – QT prolongation

7. Nucleoside/nucleotide Reverse Transcriptase Inhibitors (NRTIs). Didanosine (ddI) – high risk patient

– Increase the risk of pancreatitis with alcohol use, pancreatitis, and IV pentamidine

8. Nucleoside/nucleotide Reverse Transcriptase Inhibitors (NRTIs). Didanosine (ddI) – Lifespan considerations

– Children
approved in 6 years + weighing 20kg

– Pregnancy

less risk